News

Pasithea Therapeutics Explores New Frontiers in NF1 Treatment

Pasithea Therapeutics Explores New Frontiers in NF1 Treatment

Exciting Advances in Neurofibromatosis Research

In the ever-evolving field of biotechnology, Pasithea Therapeutics Corp. (Nasdaq: KTTA) stands out for its commitment to developing innovative treatments. Recently, the company announced the activation of a new clinical trial site at an esteemed university, enhancing its ability to evaluate PAS-004, an oral MEK inhibitor aimed at treating adult patients with neurofibromatosis type 1 (NF1). This advancement brings a sense of hope to many who are affected by this condition.

Key Developments at the University of Alabama

Located at the University of Alabama at Birmingham, this newly activated site will play a crucial role in the ongoing Phase 1/1b study. The focus is clear: to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PAS-004 in adults suffering from symptomatic and inoperable plexiform neurofibromas. This expansion represents a significant step forward in Pasithea’s commitment to tackling NF1.

Collaborative Efforts to Enhance Patient Care

Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea, expressed his enthusiasm about the collaboration with UAB. He stated that UAB's comprehensive expertise in NF1 and dedication to improving patient care are vital assets as they advance PAS-004 through clinical development. This partnership not only strengthens their research but also emphasizes the importance of community engagement, as shown by their platinum sponsorship of an upcoming symposium for NF caregivers.

Community Engagement and Education

Pasithea's involvement in the NF Caregivers Symposium highlights its dedication to the NF community. Set to take place at UAB, this event provides a platform for caregivers, clinicians, and advocates to share insights, research, and support systems aimed at enhancing the quality of life for families impacted by NF1. This initiative showcases Pasithea's commitment to not just research but also education and community involvement.

Importance of Collaborative Research

Collaboration among academic institutions, industry leaders, and patient advocates is vital for advancing the understanding and treatment of NF1. Dr. Rebecca Brown, Director of NF Clinical Programs at UAB, noted that such partnerships improve care outcomes significantly. The involvement of entities like Pasithea in clinical trials and community events fosters an environment of shared knowledge and resources, which ultimately benefits patients.

Understanding the Clinical Trial: PAS-004

The ongoing Phase 1/1b study has a dual focus: it aims to evaluate both the safety and efficacy of PAS-004. Participants in the trial will receive the medication over a structured treatment cycle, which includes a dose escalation phase to establish optimal dosing levels. This study not only assesses the direct impact of PAS-004 on plexiform neurofibromas but also explores its potential effects on quality of life and associated symptoms.

Trial Structure and Objectives

The study is designed in two parts. The first phase, or Part A, involves sequential enrollment of up to 24 eligible participants. They will receive varying doses of PAS-004 to identify the recommended phase 2 dose (RP2D). Following this, Part B will allow approximately 24 participants to continue the trial, focusing on optimal dosing over an extended period. Through this structured approach, Pasithea aims to gather robust data to support the potential for PAS-004 as a viable treatment for NF1 patients.

About Pasithea Therapeutics

Pasithea Therapeutics Corp. is not only focused on PAS-004. The company continues to investigate other therapeutic options and expand its pipeline, ensuring a broader impact in various areas of disease, including RASopathies and MAPK pathway-driven tumors. Their ongoing dedication to research and development underlines their mission to advance medical outcomes and improve patients’ lives.

Frequently Asked Questions

What is PAS-004?

PAS-004 is a next-generation macrocyclic oral MEK inhibitor being tested for effectiveness in treating adult patients with neurofibromatosis type 1 (NF1).

Where is the new clinical trial site located?

The new clinical trial site is located at the University of Alabama at Birmingham (UAB).

What are the main goals of the clinical trial?

The main goals are to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PAS-004 on targeted neurofibromas.

When does patient enrollment begin?

Enrollment at the UAB trial site is expected to commence immediately.

How does Pasithea engage with the NF community?

Pasithea actively participates in community events, such as the NF Caregivers Symposium, to support and educate caregivers and patients.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 101

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 79

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 129

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 99

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 104

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading
Envision’s COP31 Pitch Hinges on Grid Execution, Not Targets

Updated Category News Views 93

A 2,500 GW traffic jam is a rotten place to park climate ambition. Envision Energy used COP31 in Antalya to make the more useful point: clean-power targets mean very little if grids cannot connect, balance and dispatch the electricity. Kane Xu’s message was not another round of flag-waving promises. It was an argument that the constraint has shifted from wanting...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 33

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 218

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 136

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Mindgruve's Tech Hire Puts Sightline Growth in Focus

Updated Category News Views 23

Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...

Continue Reading

Top 5 Most Recently Viewed Articles

Helium One Global Ltd Advances Development Drilling Project

Updated Category News Views 381

Helium One Global Ltd Advances Development Drilling Project Helium One Global Ltd (LON: HE1H) (AIM: HE1), a notable helium exploration firm, has embarked on a significant journey with its development drilling at the Galactica-Pegasus project. This project, indicating Helium One's ambition to be a prominent figure in the helium sector, is located in Las Animas County,...

Continue Reading
FieldRoutes Introduces Innovative Features for Service Businesses

Updated Category News Views 77

FieldRoutes Enhances Service Management with Bundles Field service businesses are constantly seeking innovative ways to improve efficiency and customer satisfaction, and at the recent PestWorld conference, FieldRoutes stepped up to the plate. This leading cloud-based and mobile SaaS provider has unveiled its exciting new Bundles feature, aimed at elevating service...

Continue Reading
Exciting Updates on JLT Mobile Computers' Upcoming Meeting

Updated Category News Views 289

Invitation to the Annual General Meeting of JLT Mobile Computers JLT Mobile Computers AB (publ) is inviting its valued shareholders to participate in the Annual General Meeting (AGM). This significant event is set to take place on a Wednesday at 4:00 pm at PM & Vänner Hotel. Eligibility to Attend the Meeting To attend the meeting, it is essential that shareholders are...

Continue Reading
Ambius Collaborates to Transport Historic Trees for Remembrance

Updated Category News Views 214

Ambius Partners in an Environmental Tribute Ambius, a well-known provider of interior landscaping and plant services, has joined hands with the Anne Frank Center USA to undertake an inspiring project. This collaboration involves transporting sapling trees that are direct descendants of the historic horse chestnut tree that grew outside of Anne Frank's hiding spot. These...

Continue Reading
Caterpillar Foundation Celebrates $1 Billion in Charitable Impact

Updated Category News Views 259

Caterpillar Foundation Reaches $1 Billion Global Giving Milestone Since its inception, the Caterpillar Foundation has made remarkable strides in philanthropy, aiding over 11,000 charities across diverse regions. Recently, it achieved an inspiring milestone by surpassing $1 billion in global donations. This achievement underscores the Foundation's steadfast commitment to...

Continue Reading